Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01476423 · ClinicalTrials.gov registry record
Observational Registry of the Treatment of Glanzmann's Thrombasthenia
A clinical trial, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- 218
- Enrollment target
NCT01476423: Completed study, sponsored by Novo Nordisk A/S.
NCT01476423 is a clinical trial that has completed, run by Novo Nordisk A/S. The registered enrollment target is 218 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01476423 has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- 218 participants
- Enrollment target
Study Summary
This observational registry is conducted in Europe, Asia, Africa and the United States of America (USA). The purpose of the registry is to evaluate the efficacy and safety of activated recombinant human factor VII (rFVIIa) during bleeding episodes and for the prevention of bleeding during invasive procedures/surgery in patients with Glanzmann's thrombasthenia (GT) with past or present refractoriness to platelet transfusions. Attention will be directed towards complications related to thrombo-embolic events and concomitant medications especially antifibrinolytics.
Interventions
- DRUG activated recombinant human factor VII
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 218 participants |
| Start Date | 2004-01 |
| Est. Completion | 2011-10 |
What the finished NCT01476423 record still lists
NCT01476423 is an observational study that tracks outcomes without assigning an intervention. The registered 218 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which activated recombinant human factor VII is the first listed.
NCT01476423 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01476423 about?
NCT01476423 is a clinical study titled "Observational Registry of the Treatment of Glanzmann's Thrombasthenia". This observational registry is conducted in Europe, Asia, Africa and the United States of America (USA). The purpose of the registry is to evaluate the efficacy and safety of activated recombinant human factor VII (rFVIIa) during bleeding episodes and for the prevention of bleeding during invasive ...
What is the current status of trial NCT01476423?
This trial is currently completed. The enrollment target is 218 participants. The study started on 2004-01. Estimated completion is 2011-10.
What interventions are being tested in trial NCT01476423?
The interventions under investigation include: activated recombinant human factor VII (DRUG).
Who is sponsoring clinical trial NCT01476423?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04693858 · 218 participants · NA
Efficacy Trial of the CALM Intervention
- NCT05909202 · 218 participants · NA
A Nature-Based Virtual Reality (VR) Intervention in Family Caregivers of Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients
- NCT06000761 · 218 participants · NA
Frequent Standardized Oral Care Using Human Milk in the Neonatal Intensive Care Unit
- NCT06249126 · 218 participants · NA
Primary Subtalar Arthrodesis for Calcaneal Fractures
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia